Sawai Urges Japan To Take 'Best And Only Chance' To Reform Pricing Amid Generic Crisis
Kenzo Sawai, president of Japanese generics giant Sawai Pharmaceutical, tells Scrip in the first of a two-part exclusive interview about the firm’s strategy and backstory of efforts to maintain product supplies amid the country’s ongoing generic crisis. He also urges Japan to take "the best and only chance" to reform its drug pricing system to help the entire market survive.
Japan Progresses 'Urgent Approval' System To Speed Drug Access
Japan is intending to revise existing pharma legislation to enable the urgent approval of new drugs with "assumed efficacy", with a maximum three-year period for confirmation, in cases of emergency need. The government will also ask companies to implement tighter safety monitoring and management of supply chains, with swift data disclosure required, as part of the planned changes.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.